June 8, 2023
Rashmin Savani, MBChB, Head of Scientific Advisory Board, Azome Therapeutics, presented results of preclinical research supporting the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform at the 14th conference of the International Society for Hyaluronan Sciences held this week in Portland, Oregon.
April 17, 2023
Azome Therapeutics, an early stage drug discovery company, announced the appointment of Stavros Garantziotis, MD to its Scientific Advisory Board. Dr. Garantziotis is the Medical Director of the NIEHS Clinical Research Unit, and Adjunct Professor in the Department of Medicine at Duke University Medical School.
April 7, 2023
Azome Therapeutics, an early stage drug discovery company, announced the appointment of Ulrich H. Von Andrian, MD to its Scientific Advisory Board. Dr. Von Andrian is the Edward Mallinckrodt Jr. Professor of Immunopathology, Microbiology and Immunobiology at Harvard Medical School, and Senior Investigator at the Von Andrian Lab at Boston Children's Hospital.
